8-K current report · filed Aug 26, 2026

Generate Biomedicines Inc (GENB) 8-K Current Report: August 26, 2026

Item 7.01GENB overview

Short answer

Generate Biomedicines Inc (GENB) filed an 8-K current report with the SEC on August 26, 2026 reporting Item 7.01 (Regulation FD Disclosure). ERS posters disclose ongoing GB-0895 clinical-trial results in severe asthma and COPD.

Generate Biomedicines Inc 8-K event analysis

AI summary of each reported item and its exhibits

Item 7.01 · Regulation FD Disclosure

  • ERS posters disclose ongoing GB-0895 clinical-trial results in severe asthma and COPD
  • Data support potential twice-yearly subcutaneous dosing for asthma patients
  • Two Phase 3 SOLAIRIA studies evaluate GB-0895 in severe uncontrolled asthma
  • Final posters attached as Exhibit 99.1, enabling investor review of efficacy and pharmacologic-activity data

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Generate Biomedicines Inc 8-K filings

Get the next GENB 8-K as it lands

Follow GENB for push alerts, or ask the research agent what this filing means.